FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
 and Lead Plaintiff Deadline: March 13, 2017 - EconoTimes)
NEW YORK, Jan. 16, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fenix Parts, Inc. (“Fenix” or the “Company”) (Nasdaq:FENX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Fenix securities between May 14, 2015 and October 12, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/fenx.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fenix had an insufficient inventory valuation methodology; (2) Fenix had an incompetent methodology to calculate goodwill impairment; (3) Fenix was involved and/or had been involved in conduct that would result in an SEC investigation; and (4) consequently, Defendants’ statements about Fenix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/fenx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Fenix you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
